Science and Research

Lower Prevalence of Osteoporosis in Patients with COPD Taking Anti-Inflammatory Compounds for the Treatment of Diabetes: Results from COSYCONET

BACKGROUND: Patients with chronic obstructive pulmonary disease (COPD) often have osteoporosis and diabetes as comorbid conditions. Anti-diabetic medication, including metformin, has protective effects on osteoporosis in experimental studies. We therefore studied whether patients with COPD receiving anti-diabetic medication had a lower osteoporosis prevalence in a large COPD cohort, COSYCONET. METHODS: Assessment of osteoporosis was based on patients' reports of physician-based diagnoses and the presence of disease-specific medication. The predictive value of physical characteristics, lung function, comorbidities, cardiovascular medication, and the use of anti-inflammatory diabetes medication, including metformin, sulfonylureas, glinides or DPP4I, was evaluated using logistic regression analysis. ClinicalTrials.gov: NCT01245933. RESULTS: In total, 2222 patients were eligible for analysis (863 [39%] female, mean age 65 y), 515 of whom had higher symptoms and exacerbations (Global Initiative for Chronic Obstructive Lung Disease group D). Osteoporosis was present in 15.8% of the overall cohort, and in 24.1% of GOLD D patients. Regression analyses identified the following as associated with osteoporosis (p < 0.05): female sex, higher age, lower body-mass index, asthma, higher air trapping, oral steroids, and cardiovascular medication. Although oral anti-diabetic medication was overall not associated with a lower prevalence of osteoporosis (p = 0.131), anti-inflammatory anti-diabetic medication (p = 0.009) and metformin-containing therapy (p = 0.039) were. This was driven by GOLD D patients. CONCLUSION: In a large COPD cohort, anti-inflammatory diabetes therapy, including metformin, was associated with a lower prevalence of osteoporosis, especially in patients with higher symptoms and exacerbations. These findings suggest a protective effect of common anti-diabetic medication on osteoporosis, possibly as a result of attenuated systemic inflammation.
  • Kahnert, K.
  • Jörres, R. A.
  • Lucke, T.
  • Trudzinski, F. C.
  • Mertsch, P.
  • Bickert, C.
  • Ficker, J. H.
  • Behr, J.
  • Bals, R.
  • Watz, H.
  • Welte, T.
  • Vogelmeier, C. F.
  • Alter, P.

Keywords

  • anti-inflammatory
  • chronic obstructive pulmonary disease
  • diabetes
  • inhaled corticosteroids
  • metformin
  • oral corticosteroids
Publication details
DOI: 10.2147/copd.S335029
Journal: Int J Chron Obstruct Pulmon Dis
Pages: 3189-3199 
Work Type: Original
Location: Assoziierter Partner, ARCN, BREATH, CPC-M, TLRC, UGMLC
Disease Area: COPD
Partner / Member: COSYCONET, Ghd, KUM, MHH, Thorax, UMR
Access-Number: 34853511

DZL Engagements

chevron-down